EMEA-002618-PIP04-23 - paediatric investigation plan

ruxolitinib (phosphate)
PIP Human

Key facts

Invented name
  • Jakavi
  • Opzelura
Active substance
ruxolitinib (phosphate)
Therapeutic area
Skin and subcutaneous tissue disorders
Decision number
P/0034/2024
PIP number
EMEA-002618-PIP04-23
Pharmaceutical form(s)
Cream
Condition(s) / indication(s)
Treatment of prurigo nodularis
Route(s) of administration
Cutaneous use
Contact for public enquiries

Incyte Biosciences Distribution B.V. 
E-mail: RA@incyte.com
Tel. +1 3024252734

Decision type
W: decision granting a waiver in all age groups for all conditions or indications
Decision date
Compliance check done
No

Decision

Share this page